Core Viewpoint - Medline Inc. has successfully completed the largest IPO in the U.S. this year, raising $6.26 billion with a final pricing of $29 per share for 216 million shares, leading to a market valuation of approximately $39 billion [1][2]. Group 1: IPO Details - The IPO is set to officially launch on the Nasdaq under the ticker "MDLN" on December 17, 2025, after an increase in the offering size [1]. - Medline's IPO fundraising exceeds that of the largest global IPO this year, which was $5.26 billion by Chinese battery manufacturer CATL, and also surpasses the $1.75 billion raised by Venture Global in January [2]. - This transaction marks the largest majority stake IPO ever executed by a private equity-controlled company, surpassing the $5.1 billion IPO of Lineage Inc. last year [2]. Group 2: Company Background - Medline was founded in 1966 by Jon Mills and Jim Mills, with the Mills family remaining the largest individual shareholders post-IPO, holding 17.8% of the voting rights [4]. - The company produces and distributes medical supplies used by hospitals and physicians, offering approximately 335,000 surgical products and achieving next-day delivery to 95% of U.S. customers [4]. - As of September 27, the company reported revenues of $20.6 billion and a net profit of $977 million for the nine months, compared to $18.7 billion in revenue and $911 million in net profit during the same period last year [4]. Group 3: Shareholder Composition - Major shareholders include private equity giants Blackstone, Carlyle Group, and Hellman & Friedman, each holding 18% of the voting rights after the transaction [4]. - The Mills family and affiliates have expressed interest in purchasing up to $250 million worth of stock in the IPO [4]. Group 4: Market Context - Over the past decade, only five companies have raised more than $5 billion in IPOs in the U.S., with Medline's $6.26 billion placing it among them, alongside Uber, Lineage, Rivian Automotive, and Arm Holdings [3]. - The total IPO fundraising in the U.S. (excluding SPACs) has exceeded $46 billion this year, although it remains slightly below the pre-pandemic average of nearly $50 billion per year [3].